Denis Larsimont

Research interests

Publications

• Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

  The Lancet · 2019 · 10.1016/s0140-6736(18)33137-4

• Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer

  JCI Insight · 2019 · 10.1172/jci.insight.129641

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000162

• CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer

  JCI Insight · 2017 · 10.1172/jci.insight.91487

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000161

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer

  OncoImmunology · 2016 · 10.1080/2162402x.2016.1257452

• Genomic Characterization of Primary Invasive Lobular Breast Cancer

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.0334

• Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome

  Cell Reports · 2015 · 10.1016/j.celrep.2015.09.032

• Subclonal diversification of primary breast cancer revealed by multiregion sequencing

  Nature Medicine · 2015 · https://doi.org/10.1038/nm.3886

• Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

  Annals of Oncology · 2014 · 10.1093/annonc/mdu288

• CD4+ follicular helper T cell infiltration predicts breast cancer survival

  Journal of Clinical Investigation · 2013 · https://doi.org/10.1172/jci67428

• DNA methylation profiling reveals a predominant immune component in breast cancers

  EMBO Molecular Medicine · 2011 · 10.1002/emmm.201100801

• PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

  Proceedings of the National Academy of Sciences · 2010 · 10.1073/pnas.0907011107

• High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.2025

• Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.12.9437

• Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

  Clinical Cancer Research · 2008 · https://doi.org/10.1158/1078-0432.ccr-07-4756

• Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

  British Journal of Cancer · 2007 · https://doi.org/10.1038/sj.bjc.6603756

• Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.07.1522

• Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj052

• Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

  Annals of Oncology · 2005 · 10.1093/annonc/mdi352

• Identification of molecular apocrine breast tumours by microarray analysis

  Oncogene · 2005 · 10.1038/sj.onc.1208561

• Identification of molecular apocrine breast tumours by microarray analysis

  Breast Cancer Research · 2005 · 10.1186/bcr1122

• HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

  PubMed · 2002

• Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

  Annals of Oncology · 2002 · 10.1093/annonc/mdf252

• Chromogenic in Situ Hybridization

  American Journal Of Pathology · 2000 · 10.1016/s0002-9440(10)64785-2

Current projects

No projects listed.